Efficacy of Fuzheng Huayu Tablets for Treating Pulmonary Inflammation in COVID-19 Patients.

Objective:To observe the efficacy and safety of Fuzheng Huayu tabletsFHTfor treating pulmonary inflammation in patients with coronavirus disease 2019COVID-19. Method(s):A total of 704 cases were lost to follow-up, and 66 cases were finally completedCOVID-19 patients were recruited from February 1 to April 15 in 2020. They were assigned to a control group35 patientsand a FHT group31 patients. The patients in the control group received routine treatment alone and those in the FHT group received FHT in addition to routine treatment. The primary outcome was the ratio of patients showing improvement in chest computed tomographic manifestations after 14 days. The secondary outcome measures included remission rate or progression rate of critical illness,clinical remission rate of respiratory symptoms,routine blood examination, C-reactive proteinCPRlevel,procalcitoninPCTlevel,and blood oxygen saturationSPO2 . The safety was assessed based on liver and kidney functions and adverse events. Result(s): After the 14-day treatment,the ratio of patients showing improvement in the FHT group100%was higher than that in the control group 77.1%chi2 =8.063,P<0.01. The ratio of disease stages after treatment showed no significant difference between two groups. In the FHT group,the symptoms including cough,dyspnea,and fatigue were alleviated after treatmentP<0.01. In the control group,the symptoms including fever,cough,and dyspnea were alleviatedP<0.01,while the fatigue was not relieved after treatment. No significant difference was observed in the clinical symptoms between the two groups after treatment. After treatment,the FHT group showed decreased white blood cellWBCcount and neutrophil-to-lymphocyte ratioNLRP<0.01,elevated plateletPLTlevelP<0.05,lowered CRP levelP<0.05,and no significant difference in lymphocyte LYM,hemoglobinHb,SPO2 or PCT level. The control group showed decreased NLRP<0.05and WBC countP<0.01,elevated PCT levelP<0.05,and no significant change in LYM,Hb,PLT,SPO2 or CRP level after treatment. Furthermore,the FHT group had higher PLT level than the control groupP<0.05after treatment,and other indicators had no significant differences between the two groups. The liver and kidney functions had no significant difference between the two groups after treatment. Conclusion(s): FHT can safely promote the absorption of acute pulmonary inflammation in COVID-19 patients.Copyright © 2022, China Academy of Chinese Medical Sciences Institute of Chinese Materia Medica. All rights reserved.

Efficacy of Fuzheng Huayu Tablets for Treating Pulmonary Inflammation in COVID-19 Patients

Objective：To observe the efficacy and safety of Fuzheng Huayu tablets（FHT）for treating pulmonary inflammation in patients with coronavirus disease 2019（COVID-19）. Method：A total of 70（4 cases were lost to follow-up, and 66 cases were finally completed）COVID-19 patients were recruited from February 1 to April 15 in 2020. They were assigned to a control group（35 patients）and a FHT group（31 patients）. The patients in the control group received routine treatment alone and those in the FHT group received FHT in addition to routine treatment. The primary outcome was the ratio of patients showing improvement in chest computed tomographic manifestations after 14 days. The secondary outcome measures included remission rate or progression rate of critical illness，clinical remission rate of respiratory symptoms，routine blood examination， C-reactive protein（CPR）level，procalcitonin（PCT）level，and blood oxygen saturation（SPO2 ）. The safety was assessed based on liver and kidney functions and adverse events. Result： After the 14-day treatment，the ratio of patients showing improvement in the FHT group（100%）was higher than that in the control group （77.1%）（χ2 =8.063，P<0.01）. The ratio of disease stages after treatment showed no significant difference between two groups. In the FHT group，the symptoms including cough，dyspnea，and fatigue were alleviated after treatment（P<0.01）. In the control group，the symptoms including fever，cough，and dyspnea were alleviated（P<0.01），while the fatigue was not relieved after treatment. No significant difference was observed in the clinical symptoms between the two groups after treatment. After treatment，the FHT group showed decreased white blood cell（WBC）count and neutrophil-to-lymphocyte ratio（NLR）（P<0.01），elevated platelet（PLT）level（P<0.05），lowered CRP level（P<0.05），and no significant difference in lymphocyte （LYM），hemoglobin（Hb），SPO2 or PCT level. The control group showed decreased NLR（P<0.05）and WBC count（P<0.01），elevated PCT level（P<0.05），and no significant change in LYM，Hb，PLT，SPO2 or CRP level after treatment. Furthermore，the FHT group had higher PLT level than the control group（P<0.05）after treatment，and other indicators had no significant differences between the two groups. The liver and kidney functions had no significant difference between the two groups after treatment. Conclusion： FHT can safely promote the absorption of acute pulmonary inflammation in COVID-19 patients. © 2022, China Academy of Chinese Medical Sciences Institute of Chinese Materia Medica. All rights reserved.

Analysis of clinical features in novel Coronavirus pneumonia convalescents

Background: To analyze the clinical features of convalescent individuals with novel coronavirus-infected pneumonia (novel coronavirus pneumonia) at rehabilitation station in Wuhan. Methods: 712 patients in the convalescence period of novel coronavirus pneumonia isolated and observed at the rehabilitation station were investigated by collecting their basic data, clinical syndrome features, and tongue manifestations. The clinical syndrome features were analyzed based on guidelines of Diagnosis and Treatment Plan for Novel Coronavirus-infected Pneumonia (National Health Commission of the People's Republic of China, 7th Trial Edition). Results: Cough (24.86%), chest tightness and shortness of breath (23.17%), and fatigue (16.57%) were the main symptoms of patients in the convalescence period of novel coronavirus pneumonia. Their tongue appearance was mostly characterized by redness (88.65%), thick coating (67.25%), greasy coating (49.78%) and white coating (76.86%). Conclusion: Compared with the ordinary / mild patients, cough and anorexia symptoms were more common in the severe / critical patients. In convalescent patients, red and fat tongue with thick greasy fur were common.

Phylogenetic analysis of 48 early sars-cov-2 genomes

Background: First isolated in December 2019, SARS-CoV-2 is the agent responsible for the ongoing breakout of COVID-19. Method: We curated an assembly of the first 48 full-length SARS-CoV-2 genomes isolated and sequenced across the world and performed a phylogenetic network analysis to monitor the emergence of genomic divergence in the global SARS-CoV-2 population. Results: We identified regions of the genome that have accumulated mutations producing non-synonymous changes at the protein level, suggesting ongoing adaptation of SARS-CoV-2 to its novel human host. We identified a strong L84S mutational signal in ORF8 (present in 29.16% of genomes) together with 12 variable sites in the region encoding non-structural protein Nsp3 that represent the strongest putative regions under selection in our dataset. We did not detect mutations in the coronavirus spike protein, which is reassuring for the vaccines currently available or are ongoing large-scale clinical trials. Conclusion: Our analysis provides a snapshot in time of a rapidly evolving pandemic based on available data. Our results are in line with previous findings that point to a common ancestor isolated in Wuhan that is likely to have circulated and spread worldwide. © 2021, University of Toronto. All rights reserved.